Regeneron Pharmaceuticals, Inc. — FY2023 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2023. Although the request references Q4 2023, this filing is an annual Form 10-K and primarily reports full-year results, with selected fourth-quarter disclosures.
Business context
Regeneron is a fully integrated biotechnology company focused on discovering, developing, manufacturing, and commercializing medicines for serious diseases. The company operates as one business segment. Its principal commercial products include EYLEA and EYLEA HD, Dupixent, Libtayo, Praluent, Evkeeza, Inmazeb, and other products, with significant collaboration arrangements with Sanofi, Bayer, Roche, Alnylam, and others.
Financial performance and key metrics
| Metric | 2023 | 2022 | Change |
|---|---|---|---|
| Revenue | $13.117 billion | $12.173 billion | +7.8% |
| Net product sales | $7.078 billion | $6.894 billion | +2.7% |
| Collaboration revenue | $5.503 billion | $4.914 billion | +12.0% |
| Income from operations | $4.047 billion | $4.739 billion | -14.6% |
| Net income | $3.954 billion | $4.338 billion | -8.9% |
| Diluted EPS | $34.77 | $38.22 | -9.0% |
| Operating cash flow | $4.594 billion | $5.015 billion | -8.4% |
- Margins: Operating margin was approximately 30.9% versus 39.0% in 2022; net margin was approximately 30.1% versus 35.6%; operating cash flow margin was approximately 35.0% versus 41.2%.
- Revenue mix: Sanofi collaboration revenue was $3.800 billion, Bayer collaboration revenue was $1.488 billion, and Roche collaboration revenue was $211.0 million.
- Key products: U.S. EYLEA and EYLEA HD sales were $5.885 billion, including $165.8 million from EYLEA HD launched in August 2023. Global Libtayo sales were $863.1 million. Regeneron's share of Dupixent and Kevzara collaboration profits was $3.137 billion.
- Cost structure: Research and development expense increased to $4.439 billion from $3.593 billion. Selling, general, and administrative expense increased to $2.631 billion from $2.116 billion. Stock-based compensation expense was $885.0 million.
- Cash and investments: Cash and cash equivalents were $2.730 billion, and marketable securities totaled $13.511 billion at year-end. Working capital was $16.056 billion.
- Debt and liquidity: Long-term debt was $1.983 billion and finance lease liabilities were $720.0 million. Total outstanding indebtedness was approximately $2.703 billion. The company had no borrowings under its $750.0 million revolving credit facility and remained in compliance with applicable covenants.
- Capital allocation: Capital expenditures were $718.6 million, and the company expects 2024 capital expenditures of $825 million to $950 million. Regeneron repurchased approximately $2.215 billion of common stock in 2023; $1.531 billion remained available under its repurchase authorization at year-end.
Material changes versus the prior comparable period
- Revenue increased despite the absence of U.S. REGEN-COV sales, which contributed $5.828 billion in 2021 but none in 2022 or 2023.
- EYLEA U.S. sales declined $545.0 million, primarily because of lower net pricing, lower volume, changing market dynamics, and patient transitions to EYLEA HD. EYLEA HD generated $165.8 million after its August 2023 launch.
- Dupixent and Kevzara collaboration profits increased substantially, driven by higher Dupixent sales, although the 2022 Sanofi agreement amendment increased Regeneron's development-cost reimbursement percentage from 10% to 20% of its collaboration profit share.
- Libtayo revenue increased following Regeneron's acquisition of worldwide development, commercialization, and manufacturing rights effective July 1, 2022. Regeneron recorded $324.3 million of Libtayo rest-of-world sales in 2023.
- Operating expenses increased $1.636 billion, led by higher research and development, selling and commercialization costs, and manufacturing-related expenses. The increase more than offset revenue growth and reduced operating income.
- The effective tax rate declined to 5.9% from 10.7%, reflecting greater benefits from stock-based compensation, research credits, and foreign earnings taxed at lower rates.
- Cash flow from operations declined by $420.9 million, while cash used in investing activities improved by $599.5 million compared with 2022, partly because 2022 included substantial Libtayo acquisition-related payments.
Guidance, outlook, commentary, and risks
- Management expects existing capital resources, operating cash flow, collaboration reimbursements, and available borrowing capacity to fund anticipated operating needs for the foreseeable future.
- Management expects continued substantial research and development and commercialization spending, as well as significant capital investment in Tarrytown and Rensselaer facilities.
- Key clinical and regulatory opportunities include Dupixent for COPD, EYLEA HD expansion into RVO, odronextamab for B-cell malignancies, linvoseltamab for multiple myeloma, and additional oncology, immunology, ophthalmology, and genetic-medicine programs.
- EYLEA HD received FDA approval in August 2023 after a June 2023 complete response letter related to unresolved inspection observations at third-party manufacturer Catalent. Manufacturing capacity and third-party fill/finish execution remain important risks.
- The FDA issued a complete response letter for Dupixent in chronic spontaneous urticaria because additional efficacy data were required. Results from an ongoing Phase 3 trial were expected in late 2024.
- Regeneron discontinued enrollment in the full-dose Libtayo combination cohort of REGN5678 after observing two immune-mediated Grade 5 adverse events.
- EYLEA faces biosimilar and other competitive pressure. U.S. regulatory exclusivity for EYLEA was scheduled to expire after May 17, 2024, while the timing and impact of biosimilar launches remain uncertain.
- Material legal and regulatory matters include EYLEA patent litigation and patent challenges, litigation and investigations concerning patient assistance and alleged healthcare-law violations, proceedings concerning Praluent, and litigation related to REGEN-COV.
- Regeneron remains substantially dependent on EYLEA/EYLEA HD and Dupixent. In 2023, U.S. EYLEA HD and EYLEA sales represented approximately 45% of total revenue, and two distributors represented 76% of total gross product revenue.
- Additional risks include pricing and reimbursement pressure, Medicare drug-price negotiation and inflation rebates under the Inflation Reduction Act, collaboration dependence, supply-chain concentration, clinical-trial failure, intellectual-property challenges, cybersecurity, privacy, foreign exchange, and tax uncertainties.
Most important facts for an investor to verify
- Verify the pace of EYLEA HD adoption and whether it offsets EYLEA volume, pricing, and biosimilar pressure.
- Verify Dupixent growth, the sustainability of collaboration profit sharing, and the impact of Sanofi development-cost reimbursements.
- Review the status and potential financial exposure of EYLEA patent disputes and related biosimilar launches.
- Assess the outcome and potential liabilities from Department of Justice investigations, False Claims Act matters, patient-assistance litigation, and other legal proceedings.
- Verify the timing, cost, and regulatory status of the Rensselaer fill/finish facility and planned 2024 capital expenditures.
- Monitor the $2.330 billion contingent reimbursement obligation to Sanofi and approximately $293 million obligation to Bayer.
- Evaluate pipeline milestones, including Dupixent COPD, odronextamab, linvoseltamab, and other late-stage programs, recognizing that approval and commercialization remain uncertain.
- Reconcile reported collaboration revenue and product sales with collaborator-reported sales, profit-sharing formulas, royalties, and reimbursement obligations.